CD138-/CD34- cells may actually be tumor stem cells responsible for initiation and relapse of multiple myeloma. However, effective drugs targeted at CD138-/CD34- tumor stem cells are yet to be developed. PTX-NPs proved to be a potent anticancer treatment strategy that may contribute to targeted therapy for multiple myeloma tumor stem cells in future clinical trials.
Related Pathway/CSCs feature
 Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.
Yang, C., et al. (2013). Int J Nanomedicine 8: 1439-1449.. [ 23610522 ]